{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:18:18Z","timestamp":1746591498387,"version":"3.40.5"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.msard.2025.106353","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:16:05Z","timestamp":1740557765000},"page":"106353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical opinions and case studies on understanding and managing hypogammaglobulinaemia in multiple sclerosis: United Kingdom perspective"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-9922","authenticated-orcid":false,"given":"Sharmilee","family":"Gnanapavan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angray","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Giovanonni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2025.106353_bib0001","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1081-1206(10)60665-5","article-title":"Assessment and clinical interpretation of reduced IgG values","volume":"99","author":"Agarwal","year":"2007","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"6","key":"10.1016\/j.msard.2025.106353_bib0002","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jaci.2013.01.036","article-title":"Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement","volume":"131","author":"Agarwal","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106353_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106353_bib0004","article-title":"Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?","volume":"11","author":"Bajaj","year":"2020","journal-title":"Front. Physiol."},{"issue":"14","key":"10.1016\/j.msard.2025.106353_bib0005","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"Suppl 15","key":"10.1016\/j.msard.2025.106353_bib0006","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1212\/WNL.96.15_supplement.1300","article-title":"Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis (RMS) patients from the phase 3 ASCLEPIOS I and II trials (1300)","volume":"96","author":"Bar-Or","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2025.106353_bib0007","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1007\/s10072-022-06287-2","article-title":"Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies","volume":"43","author":"Bellinvia","year":"2022","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2025.106353_bib0008","first-page":"1","article-title":"The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation","volume":"46","author":"Benner","year":"1981","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2025.106353_bib0009","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.msard.2025.106353_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/viru.26516","article-title":"The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?","volume":"5","author":"Boomer","year":"2014","journal-title":"Virulence"},{"issue":"3","key":"10.1016\/j.msard.2025.106353_bib0011","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11940-013-0232-y","article-title":"B-cell targeting agents in the treatment of multiple sclerosis","volume":"15","author":"Braley","year":"2013","journal-title":"Curr. Treat. Options Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106353_bib0012","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40120-022-00349-5","article-title":"A targeted literature search and phenomenological review of perspectives of people with multiple sclerosis and healthcare professionals of the immunology of disease-modifying therapies","volume":"11","author":"Burtchell","year":"2022","journal-title":"Neurol. Ther."},{"issue":"7","key":"10.1016\/j.msard.2025.106353_bib0013","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1177\/13524585211061343","article-title":"Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within multiple sclerosis partners advancing technology and health solutions","volume":"28","author":"Cohen","year":"2022","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106353_bib0014","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.coi.2009.07.003","article-title":"Genetics of hypogammaglobulinemia: what do we really know?","volume":"21","author":"Conley","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.msard.2025.106353_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103264","article-title":"Acting centrally or peripherally: a renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis","volume":"56","author":"Correale","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106353_bib0016","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40120-022-00341-z","article-title":"COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab","volume":"11","author":"Cross","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106353_bib0017","unstructured":"Derfuss, T., Weber, M.S., Highes, R., et al., 2019. Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Proceedings of the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Stockholm, Sweden."},{"key":"10.1016\/j.msard.2025.106353_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104148","article-title":"Hypogammaglobulinemia: a contributing factor to multiple sclerosis fatigue?","volume":"68","author":"Diem","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106353_bib0019","doi-asserted-by":"crossref","first-page":"AB10","DOI":"10.1016\/j.jaci.2013.12.062","article-title":"Hypogammaglobulinemia, multiple sclerosis, and treatment with intravenous gammaglobulin","volume":"133","author":"Dy","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106353_bib0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s10875-017-0469-4","article-title":"Prescribing immunoglobulin replacement therapy for patients with non-classical and secondary antibody deficiency: an analysis of the practice of clinical immunologists in the UK and Republic of Ireland","volume":"38","author":"Edgar","year":"2018","journal-title":"J. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2025.106353_bib0021","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/IMT.15.74","article-title":"Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities","volume":"7","author":"Eibl","year":"2015","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.msard.2025.106353_bib0022","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/01926230600939989","article-title":"Enhanced histopathology of mucosa-associated lymphoid tissue","volume":"34","author":"Elmore","year":"2006","journal-title":"Toxicol. Pathol."},{"issue":"6","key":"10.1016\/j.msard.2025.106353_bib0023","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/eji.202149757","article-title":"Multiple sclerosis: immunopathological heterogeneity and its implications","volume":"52","author":"Engelhardt","year":"2022","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2025.106353_bib0024","article-title":"A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis","volume":"6","author":"Evertsson","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106353_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102859","article-title":"Seroconversion rate following HBV vaccination in clinical practice: the role of age and DMT treatment","volume":"50","author":"Faustino","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106353_bib0026","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement","volume":"62","author":"Freedman","year":"2005","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106353_bib0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106353_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103798","article-title":"Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab","volume":"62","author":"Habek","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106353_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.717873","article-title":"Diagnostic vaccination in clinical practice","volume":"12","author":"Hansen","year":"2021","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2025.106353_bib0030","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult. Scler."},{"year":"2023","series-title":"Hypogammaglobulinemia","author":"Huq","key":"10.1016\/j.msard.2025.106353_bib0031"},{"issue":"3","key":"10.1016\/j.msard.2025.106353_bib0032","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cei\/uxac091","article-title":"B cells defined by immunoglobulin isotypes","volume":"210","author":"James","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2025.106353_bib0033","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-015-0092-y","article-title":"Health-related quality of life in patients with primary immunodeficiency disease","volume":"11","author":"Jiang","year":"2015","journal-title":"Allergy Asthma Clin. Immunol."},{"year":"2023","series-title":"Immunoglobulin","author":"Justiz Vaillant","key":"10.1016\/j.msard.2025.106353_bib0034"},{"key":"10.1016\/j.msard.2025.106353_bib0035","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231162661","article-title":"The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study","volume":"16","author":"Klein","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106353_bib0036","series-title":"Fetal and Neonatal Physiology","first-page":"1158-67.e3","article-title":"Host defence mechanisms against bacteria","author":"Kollman","year":"2021"},{"issue":"3","key":"10.1016\/j.msard.2025.106353_bib0037","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"23","key":"10.1016\/j.msard.2025.106353_bib0038","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106353_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103719","article-title":"Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications","volume":"60","author":"Levit","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106353_bib0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000654","article-title":"Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF","volume":"7","author":"Mohn","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"year":"2017","series-title":"Janeway\u2019s Immunobiology","author":"Murphy","key":"10.1016\/j.msard.2025.106353_bib0041"},{"key":"10.1016\/j.msard.2025.106353_bib0043","first-page":"1","article-title":"Hypogammaglobulinemia and infection risk in an ocrelizumab-treated multiple sclerosis cohort","author":"Nobile","year":"2024","journal-title":"Can. J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2025.106353_bib0044","first-page":"e29703","article-title":"Suspected pediatric-onset common variable immune deficiency (CVID) in a seven-year-old female with pulmonary manifestations","volume":"14","author":"Noor","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.msard.2025.106353_bib0045","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106353_bib0042","unstructured":"National Health Service, 2023. \"Shingles vaccine.\" Retrieved 17 July 2024, from https:\/\/www.nhs.uk\/vaccinations\/shingles-vaccine\/."},{"key":"10.1016\/j.msard.2025.106353_bib0046","unstructured":"Oxford University Hospitals NHS Foundation Trust, 2022. \"Immunoglobulins.\" Retrieved 05 April 2023, from https:\/\/www.ouh.nhs.uk\/immunology\/diagnostic-tests\/tests-catalogue\/immunoglobulins.aspx."},{"issue":"1","key":"10.1016\/j.msard.2025.106353_bib0047","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106353_bib0048","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.msard.2018.07.030","article-title":"Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter?","volume":"25","author":"Pryce","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106353_bib0049","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40121-021-00404-y","article-title":"A review of vaccinations in adult patients with secondary immunodeficiency","volume":"10","author":"Righi","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.msard.2025.106353_bib0050","first-page":"1","article-title":"Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis","author":"Saidha","year":"2023","journal-title":"Neurol. Sci."},{"issue":"2 Suppl 2","key":"10.1016\/j.msard.2025.106353_bib0051","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"19","key":"10.1016\/j.msard.2025.106353_bib0052","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106353_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103735","article-title":"Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies","volume":"60","author":"Smith","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106353_bib0054","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ncomms1608","article-title":"Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential","volume":"2","author":"Stapleton","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2025.106353_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104014","article-title":"To be or not to be vaccinated: the risk of MS or NMOSD relapse after COVID-19 vaccination and infection","volume":"65","author":"Stastna","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106353_bib0056","article-title":"Decreased intrathecal concentrations of free light chains kappa in multiple sclerosis patients taking very high effective disease-modifying treatment","volume":"12","author":"Susse","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"10.1016\/j.msard.2025.106353_bib0057","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s40263-021-00863-4","article-title":"Secondary immunodeficiency and risk of infection following immune therapies in neurology","volume":"35","author":"Szepanowski","year":"2021","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.msard.2025.106353_bib0058","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12979-022-00309-5","article-title":"Aging, inflammaging and immunosenescence as risk factors of severe COVID-19","volume":"19","author":"Tizazu","year":"2022","journal-title":"Immun. Ageing"},{"issue":"2","key":"10.1016\/j.msard.2025.106353_bib0059","doi-asserted-by":"crossref","first-page":"AB16","DOI":"10.1016\/j.jaci.2018.12.051","article-title":"Hypogammaglobulinemia in multiple sclerosis patients receiving disease-modifying immunomodulatory agents","volume":"143","author":"Tsao","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2025.106353_bib0060","doi-asserted-by":"crossref","first-page":"A137","DOI":"10.1136\/jnnp-2022-ABN.441","article-title":"116 serum immunoglobulin levels and infection risk in phase 3 ofatumumab trials in relapsing multiple sclerosis","volume":"93","author":"Wiendl","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.msard.2025.106353_bib0061","article-title":"Immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab","volume":"10","author":"Ziemssen","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.msard.2025.106353_bib0062","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T15:42:47Z","timestamp":1746546167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":62,"alternative-id":["S2211034825000963"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106353","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical opinions and case studies on understanding and managing hypogammaglobulinaemia in multiple sclerosis: United Kingdom perspective","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106353"}}